Recruiting

RAI SupportTesting a Web-based Intervention for Radioactive Iodine Symptom Management to Improve Health-related Quality of Life Among Differentiated Thyroid Cancer Patients

Sponsor:

Georgetown University

Code:

NCT06853925

Conditions

Thyroid Neoplasms

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Radioactive Iodine Support (RAI Support)

Treatment as Usual (TAU)

Study Details

Brief summary:

The goal of this clinical trial is to learn if adult patients diagnosed with differentiated thyroid cancer can easily use and benefit from an online tool aimed to provide patients with educational resources and symptom management strategies to improve their quality of life after radioactive iodine (RAI) treatment. The main questions it aims to answer are:

1. Can patients easily use and benefit from the RAI Support intervention?
2. Does RAI Support improve health-related quality of life (overall well-being) compared to usual care?

This research will help test better digital tools to support thyroid cancer survivors in managing their health after RAI treatment.

Researchers will compare RAI Support to treatment as usual (a publicly available informational website about thyroid cancer) to see if RAI Support works to improve patients' overall well-being.

Participants will:

1. Receive access to RAI Support or an informational website (treatment as usual) for four weeks.
2. Use the assigned website once a week for up to four weeks.
3. Complete two online questionnaires (an initial questionnaire and a final questionnaire after four weeks of using the assigned website) about symptoms related to RAI treatment, mood, and confidence in managing symptoms.
4. Complete an optional 60 minute virtual interview about your experiencing using the assigned website.

Conditions

Thyroid Neoplasms

Study ID

NCT06853925

Start date

Oct 2, 2025

Status verified date

Jan, 2026

Completion date

Feb, 2027

Anticipated

Primary completion date

Feb, 2027

Anticipated

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Inclusion Criteria:

Age 18 or older (papillary or follicular carcinoma)
Diagnosed with differentiated thyroid cancer
Received radioactive iodine (RAI) treatment less than or equal to three years ago.
Mild to moderate symptoms of RAI
Able to provide informed consent in English
Access to a computer, tablet, or smartphone with internet connectivity

Exclusion Criteria:

A condition that precludes providing informed consent or completing study procedures (cognitive or psychiatric condition, hearing problems) as identified by the patient's physician or as assessed by a trained study team member.

Study Design

Enrollment

88 participants

Anticipated

Allocation

Randomized

Intervention Model

Parallel Assignment

Primary purpose

Supportive Care

Interventions and Outcome Measures

Arms

other: Treatment as usual (TAU)

The American Cancer Society (ACS) website on Radioactive Iodine (Radioiodine)Therapy for Thyroid Cancer is the TAU comparison. This website is a reputable and trusted source of information about cancer, with relevant content and web availability. Using the ACS website allows participants in both groups to receive information (addressing ethical concerns) through a website (similar delivery mode for information).

experimental: Radioactive Iodine Support (RAI Support)

RAI Support consists of multimedia content (images, videos, text, audio, and infographics across different website pages) that is written at an 8th grade reading level. RAI Support uses patient materials that are visually diverse to appeal to patients from different racial and ethnic backgrounds and inclusion of all genders. RAI Support users can access short (\~3 minutes or less) clinician-approved symptom management education videos and follow clinician-led video-guided activities such as nutrition management for dry mouth. In addition, RAI Support contains infographic pages about specific symptoms of RAI (e.g., salivary, lacrimal, and nasal symptoms with strategies for symptom management) and a resources page consisting of a printable treatment summary and survivorship plan to bring to provider appointments and access to evidence-based stress-management resources such as relaxation recordings.

Interventions

Radioactive Iodine Support (RAI Support)

Treatment as Usual (TAU)

Primary outcome measure

Feasibility (Retention and Engagement) [ Time Frame: 4 weeks ]
Acceptability (Quantitative) [ Time Frame: 4 weeks ]
Acceptability (Qualitative) [ Time Frame: 4 weeks ]

Central Contacts and Locations

Central contacts

Alaina L Carr, PhD

202-687-0958 cancercarestudy@georgetown.edu

Valeria Gómez, BS

cancercarestudy@georgetown.edu

Locations

Georgetown University

Recruiting

Washington D.C., District of Columbia, United States, 20007

Contacts

Alaina Carr PI, PhD

202-687-0958 alc343@georgetown.edu

More Information

Sponsor

Georgetown University

Last update posted

Jan 16, 2026

Last verified

Jan, 2026

Keywords

symptom burden
self efficacy
feasibility studies
internet-based intervention
pilot projects
neoplasms
radioactive iodine treatment
iodine radioisotopes
health-related quality of life
informational needs

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-10. This information was provided to ClinicalTrials.gov by Georgetown University on 2026-01-16.